Novavax is trading at $9.84, up +6.26%, after partners received approvals for its XFG-adapted Nuvaxovid vaccine in the United States, European Union, and Japan for the 2026–2027 season.
- Sanofi and Takeda will handle commercial activities, preserving royalty revenue without Novavax maintaining commercial infrastructure.
- Reuters independently reported FDA approval for the Novavax-Sanofi vaccine.
- Major U.S. indices are lower, making the company-specific catalyst the clearest explanation.